Basel, Switzerland / Cologne, Germany, 12. November 2012 – Lonza, a world leader in primary cells collection, announced today the launch of new Clonetics™ Fresh Human Pancreatic Islets. Lonza’s pancreatic islets possess a guaranteed quality with each batch tested for quantity (total IEQ), viability, purity, and sterility. They can be used in a variety of research areas including islet transplantation, insulin production, cell metabolism, immunosuppression, and other metabolic disorders.
Some of the major challenges within the diabetes research are the acquisition and availability of high-quality islets. Researchers will now have easy access to islets to support research in long-term islet grafting survival, prevention of islet rejection, and prevention of adverse effects from immunosuppressive drugs. The Global Head of Marketing Lonza Bioscience Research and Testing Products, Claus-Dietmar Pein states, “It is exciting to be able to offer these cells to the commercial research market due to high market interest and limited accessibility to date. This is a nice extension to our existing metabolic disease product portfolio to further advance research and drug discovery in this area.”
Allowing researchers to avoid roadblocks in Diabetes Research, the new offering enhances the comprehensive collection of Lonza’s metabolic research-based products and services.For product details and ordering information, visit www.lonza.com/islets.